PDS Biotechnology (PDSB) is scheduled to report Q4 earnings on March 26, 2026. Analysts estimate EPS of $-0.20 and quarterly revenue of N/A.
In the most recent quarter (Q3), PDS Biotechnology reported EPS of $-0.19, beating estimates of $-0.20 by 0.05%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.
PDS Biotechnology has beaten EPS estimates in 4 consecutive quarters.
Over the last 4 quarters, PDS Biotechnology has averaged an EPS surprise of 0.15% and a revenue surprise of 0.00%.
Analyze the earnings history of PDS Biotechnology using advanced sorting and filters.
The chart below shows PDS Biotechnology's reported EPS compared to analyst estimates over recent quarters.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-11-13 | $-0.19 | $-0.20 | 5.00 % |
| Q2 | 2025-08-13 | $-0.21 | $-0.24 | 12.5 % |
| Q1 | 2025-05-14 | $-0.21 | $-0.25 | 16.0 % |
| Q4 | 2025-03-27 | $-0.21 | $-0.28 | 25.0 % |
The chart below shows PDS Biotechnology's reported revenue compared to analyst estimates over recent quarters.
PDS Biotechnology (PDSB) is scheduled to report earnings on March 26, 2026. The last reported earnings were for reported on November 13, 2025 for Q3.
The Actual EPS was $-0.19, which beat the estimate of $-0.20.
The Actual Revenue was $0.00, which hit the estimate of $0.00.